Written by the Nuvirox Research Team
Key points
- Spermidine is a polyamine that induces autophagy, and its levels fall with age. The mechanism is well established in cells and animals.
- The largest human trial — SmartAge, 100 older adults with subjective cognitive decline, 12 months, 0.9 mg/day from wheat germ extract — found no significant change in its primary memory outcome (between-group difference −0.03; 95% CI −0.11 to 0.05; P = .47).
- Exploratory analyses hinted at effects on verbal memory and inflammation, and the authors flagged that a higher dose deserves testing. That is a fair reading — and it is not the same as a positive result.
Short answer: spermidine has an excellent mechanistic story and a clearly negative primary result from its best human trial. Twelve months of supplementation in 100 older adults did not change memory performance or the measured biomarkers versus placebo. The dose used was low — roughly a 10% increase in daily supply — which is the strongest available defence of the ingredient and also the reason nobody should be claiming it works yet.
What is spermidine and why did it attract attention?
Spermidine is a naturally occurring polyamine found in wheat germ, soybeans, mushrooms, aged cheeses and various fermented foods. Cells make it themselves, and tissue concentrations decline with age. Its claim to fame is as an inducer of autophagy — the cellular housekeeping process that clears damaged proteins and organelles.
Autophagy has a strong claim to being causally involved in ageing, which makes anything that reliably induces it interesting. The NAD+ connection runs through the same territory, which we cover in NAD+ and autophagy. The mitophagy-specific version of the same logic drives the urolithin A literature.
What human studies actually show
The SmartAge trial is the definitive human dataset, and it was negative. One hundred participants aged 60 to 90 with subjective cognitive decline were randomised 1:1 to a spermidine-rich wheat germ extract or microcrystalline cellulose placebo for twelve months. The primary outcome was mnemonic discrimination performance on the Mnemonic Similarity Task. Eighty-nine participants completed the intervention, with mean compliance of 95.3%.
Study snapshot
| Trial | SmartAge, ClinicalTrials.gov NCT03094546 |
| Design | Monocentre, randomised, double-masked, placebo-controlled phase 2b |
| n / population | 100 adults aged 60–90 with subjective cognitive decline |
| Dose | 750 mg wheat germ extract daily ≈ 0.9 mg spermidine |
| Duration | 12 months |
| Primary result | No significant change: between-group difference −0.03 (95% CI −0.11 to 0.05), P = .47 |
| Secondary | No significant changes. Exploratory signals on verbal memory and inflammation; adverse events balanced |
The earlier, smaller trial was suggestive rather than conclusive. A three-month randomised controlled trial in older adults at risk for dementia, published in Cortex in 2018, reported a trend toward improved hippocampal-dependent memory. It was a small study and was explicitly the basis for designing SmartAge as the larger, longer test.
The honest counterweight, and the honest defence. The counterweight is straightforward: the well-powered, year-long, pre-registered trial found nothing on its primary endpoint or its secondaries. The defence is that the dose was small. The authors themselves characterised the intervention as increasing daily spermidine supply by about 10%, and concluded that exploratory signals needed validation at a higher dosage. That is a legitimate limitation. It is also an argument that has not yet been tested, and until it is, the trial result stands.
Why did a good mechanism produce a null trial?
Three explanations are all live, and honest people disagree about which dominates.
- Dose. Roughly 0.9 mg per day against a dietary background that already supplies several milligrams is a small nudge. Autophagy induction in cell models uses concentrations that do not map onto this.
- Population and endpoint. Subjective cognitive decline is an early, heterogeneous state, and mnemonic discrimination is a specific and demanding measure. A real but small effect could be missed.
- The mechanism may not translate. Autophagy induction in a dish is not the same as clinically meaningful autophagy modulation in an ageing human brain over a year.
What spermidine won’t do
It will not act as an energy supplement. Nothing in the trial literature suggests an effect on fatigue, alertness or subjective vitality, and none of the trials measured those as primary outcomes.
It also will not fix a memory problem that has a treatable cause. Thyroid disease, B12 deficiency, obstructive sleep apnoea, depression and several medications all produce memory complaints and all have specific management.
Dose, food sources and a realistic timeline
Wheat germ is the richest common dietary source, followed by soybeans, mushrooms, aged cheeses and fermented foods. The trial dose was 750 mg of wheat germ extract delivering approximately 0.9 mg spermidine, 0.5 mg spermine and 0.2 mg putrescine, taken as six capsules daily for a year.
If a product does not disclose its actual spermidine content in milligrams, you cannot compare it to the trial at all. That is the most useful practical filter available, and it is a reasonable standard to apply to any supplement in this category. Any timeline expectation shorter than several months has no grounding in the human literature.
Frequently asked questions
Did SmartAge fail because the dose was too low?
That is the authors' own leading explanation, and it is reasonable — the intervention raised daily supply by roughly 10%. But it remains a hypothesis. Until a higher-dose trial is run, the available evidence is a null result.
Should I just eat more wheat germ?
Wheat germ is a genuinely rich dietary source and a perfectly sensible food. The honest point is that the trial used a concentrated extract at a defined dose and still found nothing, so food-based intake is unlikely to do more.
Is spermidine safe?
In SmartAge, adverse events were balanced between groups over twelve months, and 89% of participants completed the intervention. That is a reasonable safety picture at the dose studied. Higher doses have not been characterised the same way.
Does spermidine help with energy or fatigue?
No trial has tested that. The human research programme has been aimed at memory and cognition in older adults at risk of dementia, and even there the primary result was null.
How does it compare to urolithin A?
Urolithin A has trials with muscle biopsies and pre-specified functional endpoints, and produced positive secondary signals despite missing its primaries. Spermidine's largest trial found nothing on primary or secondary outcomes. Our urolithin A review covers that comparison in more detail.
From Nuvirox
Why we formulated NAD+ Restore.
We hold our own ingredients to the standard applied above: dose disclosed, within the range used in published human trials, with no claim that outruns the evidence.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Spermidine is the cleanest example in this category of a beautiful mechanism meeting a disappointing trial. Twelve months, a hundred participants, high compliance, pre-registered outcome — and no effect on memory or biomarkers. The low dose is a fair criticism and the exploratory hints are worth following up, but neither turns a null result into a positive one. If you take spermidine, take it as a bet on the higher-dose trial that has not been run yet, and check that whatever you buy actually discloses its spermidine content in milligrams. Most do not.
References
- Schwarz C, Benson GS, Horn N, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Network Open. 2022;5(5):e2213875. PMID: 35616942. PMCID: PMC9136623. ClinicalTrials.gov: NCT03094546.
- Wirth M, Benson G, Schwarz C, et al. The effect of spermidine on memory performance in older adults at risk for dementia: a randomized controlled trial. Cortex. 2018;109:181-188. PMID: 30388439.
- Wirth M, Schwarz C, Benson G, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge) — study protocol for a randomized controlled trial. Alzheimer’s Research & Therapy. 2019;11(1):36. PMID: 31039826.
- Singh P, Gollapalli K, Mangiola S, et al. Taurine deficiency as a driver of aging. Science. 2023;380(6649):eabn9257. PMID: 37289866. DOI: 10.1126/science.abn9257.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.